Suppression of adrenal ßarrestin1-dependent aldosterone production by ARBs: Head-to-head comparison

Scientific Reports

Volumn 5, Issue , 2015, Pages 8116-

  Dabul, Samalia ^a   Bathgate Siryk, Ashley ^a   Valero, Thairy Reyes ^a   Jafferjee, Malika ^a   Sturchler, Emmanuel ^b   Mcdonald, Patricia ^b   Koch, Walter J ^c   Lymperopoulos, Anastasios ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BETA ARRESTIN; CANDESARTAN; GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHOPROTEIN; RETINA S ANTIGEN; STEROIDOGENIC ACUTE REGULATORY PROTEIN; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ADRENAL GLAND; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CHO CELL LINE; COMPARATIVE STUDY; CRICETULUS; DRUG EFFECTS; HAMSTER; HUMAN; METABOLISM; RAT; UPREGULATION; ZONA GLOMERULOSA;

ADRENAL GLANDS; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; ARRESTINS; BENZIMIDAZOLES; CHO CELLS; CRICETINAE; CRICETULUS; GTP-BINDING PROTEINS; HUMANS; PHOSPHOPROTEINS; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; UP-REGULATION; VALINE; VALSARTAN; ZONA GLOMERULOSA;

EID: 84923164022     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08116     Document Type: Article

References (23)

1. Weber, K. T. Aldosterone in congestive heart failure. N. Engl. J. Med. 345, 1689-1697 (2001).
2. Rainey, W. E., Saner, K. & Schimmer, B. P. Adrenocortical cell lines. Mol. Cell. Endocrinol. 228, 23-38 (2004).
3. Luttrell, L. M.&Gesty-Palmer, D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 62, 305-330 (2010).
4. Lymperopoulos, A. et al. An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 106, 5825-5830 (2009).
5. Lymperopoulos, A. et al. Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J. Am. Coll. Cardiol. 57, 356-365 (2011).
6. Bathgate-Siryk, A. et al. Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension. 63, 404-412 (2014).
7. Sarzani, R. et al. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am. J. Hypertens. 25, 818-826 (2012).
8. Horita, Y., Taura, K., Taguchi, T., Furusu, A. & Kohno, S. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton). 11, 462-466 (2006).
9. Bomback, A. S. & Klemmer, P. J. The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3, 486-492 (2007).
10. Naruse, M. et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 40, 28-33 (2002).
11. Violin, J. D. & Lefkowitz, R. J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28, 416-422 (2007).
12. Shukla, A. K. et al. Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl. Acad. Sci. USA. 105, 9988-9993 (2008).
13. Wei, H. et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. USA. 100, 10782-10787 (2003).
14. Sheth, H. et al. A Multiplexed Fluorescent Calcium and NFAT Reporter Gene Assay to Identify GPCR Agonists. Curr. Chem. Genomics Transl. Med. 7, 1-8 (2013).
15. Michel, M. C., Foster, C., Brunner, H. R. & Liu, L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol. Rev. 65, 809-848 (2013).
16. Vanderheyden, P. M., Fierens, F. L., De Backer, J. P., Fraeyman, N. & Vauquelin, G. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors. Br. J. Pharmacol. 126, 1057-1065 (1999).
17. Vanderheyden, P. M., Fierens, F. L., De Backer, J. P. & Vauquelin, G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors. Biochem. Pharmacol. 59, 927-935 (2000).
18. Saulière, A. et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat. Chem. Biol. 8, 622-630 (2012).
19. Lymperopoulos, A. et al. Different potencies of angiotensin receptor blockers at suppressing adrenal βarrestin1-dependent post-myocardial infarction hyperaldosteronism. J. Am. Coll. Cardiol. 64, 2805-2806 (2014).
20. Eklind-Cervenka, M. et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. J. Am. Med. Assoc. 305, 175-182 (2011).
21. McGuinness, D. et al. Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assay. J. Biomol. Screen. 14, 49-58 (2009).
22. Peters,M. F. et al. Evaluation of cellular dielectric spectroscopy, a whole-cell, labelfree technology for drug discovery on Gi-coupled GPCRs. J. Biomol. Screen. 12, 312-319 (2007).
23. Ferguson, S. S. et al. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science. 271, 363-366 (1996).